Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
USE OF DAPAGLIFLOZIN FOR HEART FAILURE WITH REDUCED EJECTION FRACTION IN ITALIAN CLINICAL PRACTICE (EVOLUTION-HF ITALY): INTERIM ANALYSIS AT 6 MONTHS OF FOLLOW-UP
Anno:
2024
Background. Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor (SGLT2i) approved for the treatment of Heart Failure (HF); however, real-world data on the use of dapagliflozin in the setting of HF with reduced Ejection Fraction (HFrEF) are scarce. EVOLUTION-HF Italy is part of a wider initiative aimed at filling these gaps…
Leggi di più
SGLT2i NEL REAL WORLD: DATI DEL PROGETTO PONTE SC (PDTA PER IL FOLLOW-UP INTEGRATO OSPEDALE TERRITORIO DEL PAZIENTE CON SCOMPENSO CARDIACO)
Anno:
2024
Background Negli ultimi anni gli inibitori del cotrasporatore sodio-glucosio di tipo 2 (SGLT2i) dapaglifozin ed empaglifozin hanno dimostrato una significativa riduzione, in pazienti affetti da scompenso cardiaco a frazione d’eiezione ridotta, del rischio composito di mortalità cardiovascolare e/o di peggioramento dello scompenso cardiaco (SC). Trial più recenti hanno dimostrato…
Leggi di più
Dapagliflozin effect on cardiopulmonary, echocardiographic function, biomarkers and NYHA class in HFrEF patients
Anno:
2024
Background: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are currently a standard therapy for patients with heart failure with reduced ejection fraction (HFrEF). This study aims to assess the effects of Dapagliflozin on exercise capacity, cardiac biomarkers, fluid retention, renal and pulmonary function. Methods: We prospectively enrolled stable HFrEF outpatients (left ventricular…
Leggi di più
INDEPENDENT EFFECT OF SGLT2i ON DIASTOLIC FUNCTION IN HFrEF POPULATION
Anno:
2024
Background: Scientific literature reinforces the role of diastolic dysfunction in patients with heart failure with reduced ejection fraction (HFrEF) as an independent prognostic indicator of all-cause mortality. In this context, E/e’ ratio plays a central role in diastolic dysfunction assessments and diagnosis. Despite the introduction of several novel medical…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Cookie Policy Privacy Policy

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram